Shares of Medpace Holdings Inc. (NASDAQ: MEDP) surged 40.48% in after-hours trading on Monday, following the release of its impressive second-quarter 2025 financial results and optimistic full-year guidance. The clinical contract research organization's performance significantly exceeded analyst expectations, triggering a wave of investor enthusiasm.
Medpace reported a substantial 14.2% year-over-year increase in Q2 revenue, reaching $603.3 million and surpassing the analyst consensus estimate of $538.8 million by 12.14%. The company's earnings per share (EPS) also outperformed, coming in at $3.10, beating the analyst forecast of $2.97 by 4.45% and marking a 12.73% increase from the same period last year.
Adding to the positive sentiment, Medpace provided an upbeat outlook for the full fiscal year 2025. The company projects annual revenue between $2.42 billion and $2.52 billion, with EPS expected to range from $13.76 to $14.53. This forward-looking guidance, coupled with the strong Q2 performance, appears to have fueled investor confidence, driving the stock to trade around $432 in the after-hours session, up from its regular market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.